Antinuclear Antibodies Following Infliximab Treatment in Patients With Rheumatoid Arthritis or Spondylarthropathy

Transcription

1 ARTHRITIS & RHEUMATISM Vol. 48, No. 4, April 2003, pp DOI /art , American College of Rheumatology Antinuclear Antibodies Following Infliximab Treatment in Patients With Rheumatoid Arthritis or Spondylarthropathy Leen De Rycke, Elli Kruithof, Nancy Van Damme, Ilse E. A. Hoffman, Nancy Van den Bossche, Filip Van den Bosch, Eric M. Veys, and Filip De Keyser Objective. To investigate the effect of infliximab treatment on antinuclear antibodies (ANAs), anti double-stranded DNA (anti-dsdna), antinucleosome, antihistone, and anti extractable nuclear antigen (anti- ENA) antibodies in rheumatoid arthritis (RA) and spondylarthropathy (SpA) patients. Methods. Sera from 62 RA and 35 SpA patients treated with infliximab were tested at baseline and week 30 (RA group) or week 34 (SpA group). ANAs were tested by indirect immunofluorescence (IIF) on HEp-2 cells. Anti-dsDNA antibodies were detected by IIF on Crithidia luciliae and by enzyme-linked immunosorbent assay (ELISA) and were further isotyped with,, and chain specific conjugates at various time points. Antinucleosome antibodies were tested by ELISA. Antihistone and anti-ena antibodies were detected by line immunoassay. Results. Initially, 32 of 62 RA patients and 6 of 35 SpA patients tested positive for ANAs. After infliximab treatment, these numbers shifted to 51 of 62 (P < 0.001) and 31 of 35 (P < 0.001), respectively. At baseline, none of the RA or SpA patients had anti-dsdna antibodies. After infliximab treatment, 7 RA patients (P 0.016) and 6 SpA patients (P 0.031) became positive for anti-dsdna antibodies. All 7 anti-dsdna positive RA patients had IgM and IgA anti-dsdna antibodies. Supported by grants from the Vlaams instituut voor de bevordering van het wetenschappelijk-technologisch onderzoek in de industrie (IWT/SB/11127), the Bijzonder Onderzoeksfonds Ghent University (BOF01/DCO/068), and the Bijzonder Onderzoeksfonds Ghent University (BOF00/DOC/031). Leen De Rycke, MD, Elli Kruithof, MD, Nancy Van Damme, PhD, Ilse E. A. Hoffman, MD, Nancy Van den Bossche, MD, Filip Van den Bosch, MD, Eric M. Veys, MD, PhD, Filip De Keyser, MD, PhD: Ghent University Hospital, Ghent, Belgium. Address correspondence and reprint requests to Leen De Rycke, MD, Department of Rheumatology, Ghent University Hospital, De Pintelaan 185, B-9000 Ghent, Belgium. leenderycke@ hotmail.com. Submitted for publication October 10, 2002; accepted in revised form December 19, Three of the 6 anti-dsdna positive SpA patients had IgM and IgA anti-dsdna antibodies, and 2 had IgM anti-dsdna antibodies alone. In both diseases, the IgM anti-dsdna antibodies appeared before the IgA antidsdna antibodies. During the observation period, no IgG anti-dsdna antibodies or lupus symptoms were observed. The development of antinucleosome, antihistone, or anti-ena antibodies following infliximab treatment was observed in some patients, but the numbers were not statistically significant. Conclusion. Infliximab treatment may induce ANAs, and especially IgM and IgA anti-dsdna antibodies, in RA and SpA patients. However, no anti-dsdna IgG antibodies or lupus symptoms were observed during the period of observation in this study, and the development of antinucleosome, antihistone, or anti-ena antibodies was not statistically significant. These observations do not exclude potential induction of clinically significant lupus in the long term, and further followup is therefore mandatory. The chronic inflammatory joint diseases rheumatoid arthritis (RA) and spondylarthropathy (SpA) are the two most frequent types of autoimmune arthritis, with a prevalence rate of 1 2% (1,2). The classic treatment schemes for RA consist of a combination of disease-modifying antirheumatic drugs (DMARDs) and nonsteroidal antiinflammatory drugs (NSAIDs). SpA patients are mainly treated with NSAIDs, eventually in combination with sulfasalazine for peripheral arthritis or methotrexate (MTX) for psoriatic arthritis. This approach, however, often leads to only partial control of the inflammation and structural damage (3 5). Although the pathogenesis of RA and SpA remains incompletely understood, much insight into the cellular and molecular mechanisms involved has been gained in the last decade. Based on these insights, new therapies have been developed. One of these new strategies is the use of 1015

2 1016 DE RYCKE ET AL biologic agents directed against tumor necrosis factor (TNF ). Infliximab (Remicade; Centocor, Malvern, PA) is a chimeric anti-tnf monoclonal IgG1 antibody that neutralizes the soluble cytokine and blocks the membrane-bound cytokine. Infliximab is very effective in reducing the chronic symptoms and indicators of inflammation in patients whose RA has failed to respond to conventional DMARDs (6 11), and there is evidence that infliximab in combination with MTX halts radiologic progression in RA (10). Recently, TNF blockade has also opened new perspectives for the treatment of SpA: significant clinical and laboratory improvements in patients with active SpA treated with infliximab have been reported (12 16). Also, in patients with treatment-resistant Crohn s disease (CD), infliximab has shown to be effective in reducing the symptoms (17,18) and healing the enterocutaneous fistulas (19). Headache, nausea, upper respiratory tract infections, and infusion-related reactions are the most commonly observed adverse events with infliximab (20). However, serious adverse events, such as opportunistic infections (Mycobacterium tuberculosis, fungal and bacterial sepsis) have also been reported (20 22). Clinical trials reveal that infliximab induces autoantibodies, such as antinuclear antibodies (ANAs) and anti double-stranded DNA (anti-dsdna). According to the safety data on infliximab, 63.8% of RA patients and 49.1% of CD patients newly develop positivity for ANA during infliximab treatment, and 13% of infliximabtreated RA patients and 21.5% of infliximab-treated CD patients develop positivity for anti-dsdna antibodies (23). However, systematic studies concerning the incidence and isotype of induced autoantibodies, and especially anti-dsdna antibodies, during infliximab treatment are limited with regard to RA and nonexistent for SpA. The aim of this study was to describe the effect of infliximab treatment on ANAs, anti-dsdna antibodies, and other antinuclear reactivities (antinucleosome antibodies, antihistone antibodies, and anti extractable nucler antigen [anti-ena] antibodies), with special reference to the isotyping and the timing of induction of the anti-dsdna antibodies in the context of infliximab treatment. PATIENTS AND METHODS Patients and medication regimen. Sixty-two patients (24 men and 38 women; mean age at baseline 53.9 years [range 32 76]) with refractory RA, treated with infliximab at one center in the context of an expanded access program, were included in the study (24). All patients fulfilled the American College of Rheumatology (ACR; formerly, the American Rheumatism Association) classification criteria for RA (25). They received 3 mg/kg infliximab intravenously at weeks 0, 2, 6, and every 8 weeks thereafter, in combination with MTX. Thirty-five patients (23 men and 12 women; mean age at baseline 46.6 years [range 29 66]) with active SpA were treated with infliximab in a placebo-controlled trial in which the placebo group received active treatment with infliximab after 12 weeks (15). All patients fulfilled the European Spondylarthropathy Study Group classification criteria for SpA (26). The treatment schedule was a loading-dose regimen (intravenous infusions at weeks 0, 2, and 6) of 5 mg/kg infliximab, followed by 10 mg/kg infliximab every 14 weeks (15). Originally, 40 SpA patients were included in the placebo-controlled trial with infliximab. In the active treatment group (n 20), infliximab treatment was stopped in 3 patients before week 34, due to M tuberculosis infection (n 1), a diagnostic procedure related adverse event (n 1), and withdrawal from the study for personal reasons (n 1). In the placebo group (n 20), no dropouts were reported during the placebo treatment period, but during the infliximab treatment, 2 patients were withdrawn from the study before week 34, due to M tuberculosis infection (n 1) and a protocol violation by the patient (n 1). Since both groups received the same regimen, we pooled the remaining SpA patients treated with infliximab (n 35). In the RA patients, serum samples were obtained at baseline prior to infusion and at the time of each infusion up to week 30 (weeks 0, 2, 6, 14, 22, and 30). In the SpA patients, serum samples were obtained at baseline prior to infusion, at the time of each infusion up to week 34 (weeks 0, 2, 6, 20, and 34), and at week 12. Serum was obtained by clotting through centrifugation and was aliquoted at 20 C until further analysis. Serum samples were collected after informed consent from the patients and approval by the local ethics committee were obtained. Detection of ANAs. Serum diluted 1:40 in phosphate buffered saline (PBS) was overlaid onto fixed HEp-2 cells (MeDiCa, Carlsbad, CA). Slides were washed twice for 5 minutes each with PBS, overlaid with fluorescence-labeled conjugate (anti-human IgG heavy and light chain specific; MeDiCa), and incubated for an additional 30 minutes. After washing twice, a coverslip was placed over the slide, and the slides were read using a fluorescence microscope at 40 power. The fluorescence intensity was scored semiquantitatively from 1 to 5 relative to the intensity of a negative and a positive (4 ) control (27). The fluorescence pattern was also reported. Detection of anti-dsdna antibodies. For the initial screening of anti-dsdna antibodies, serum samples obtained at baseline and at week 30 or 34 were tested by indirect immunofluorescence (IIF) on Crithidia luciliae and by antidsdna enzyme-linked immunosorbent assay (ELISA) (see below), using an anti-human IgG heavy and light chain specific conjugate in both assays. A patient was classified as having anti-dsdna antibodies only when a positive result was confirmed in both anti-dsdna assays. Serum samples from patients with anti-dsdna antibodies according to this definition were further isotyped with,, and chain specific

3 ANAs IN RA AND SpA PATIENTS TREATED WITH INFLIXIMAB 1017 conjugates and were tested at various time points in order to determine the moment anti-dsdna antibodies appeared. IIF on C luciliae. C luciliae coated slides (MeDiCa) were used for the detection of anti-dsdna antibodies. Serum samples diluted 1:20 in PBS were incubated for 30 minutes at room temperature. As in the ANA experiments, slides were washed twice for 5 minutes each with PBS, overlaid with fluorescence-labeled conjugate (anti-human IgG heavy and light chain specific; MeDiCa), and incubated for an additional 30 minutes. After washing twice, a coverslip was placed over the slide, and the slides were read using a fluorescence microscope at 40 power. IIF on C luciliae was also used for isotyping of the anti-dsdna antibodies. For the detection of anti-dsdna antibodies of the IgG, IgM, or IgA class, we used specific conjugates against human IgG heavy ( ) chain (P.A.R.I.S, Compiègne, France), human IgM heavy ( ) chain (Dako, Glostrup, Denmark), and human IgA heavy ( ) chain (Dako). Anti-dsDNA ELISA. A commercially available kit (Varelisa dsdna antibodies; Pharmacia Diagnostics, Freiburg, Germany) was used for the detection of anti-dsdna antibodies. The ELISA was performed according to the manufacturer s instructions. Briefly, the wells were washed once with 300 l wash buffer immediately prior to use. Subsequently, 100 l of standards, controls, and patient samples (1:100) were dispensed into the appropriate wells. After 30 minutes of incubation, the fluid was aspirated from the wells and the wells were washed 3 times with wash buffer. In a second step, 100 l of conjugate (anti-human IgG heavy and light chain specific, coupled with horseradish peroxidase) was added to the wells. After incubation for 30 minutes, the wells were washed 3 times with wash buffer. Thereafter, 100 l of enzyme substrate (3,3,5,5 -tetramethylbenzidine) was dispensed into the wells. After incubation for 10 minutes in the dark, 50 l of stop solution (0.5M H 2 SO 4 ) was dispensed into all wells. The absorbance (optical density [OD]) was read at 450 nm. According to the manufacturer s instructions, a result of 35 IU/ml was considered positive. Detection of antinucleosome antibodies. A commercially available kit (Medizym antinucleo; Medipan Diagnostica, Selchow, Germany) was used for the detection of antinucleosome antibodies. The ELISA was performed according to the manufacturer s instructions. Briefly, 100 l of standards, controls, and patient samples (1:50) was dispensed into the appropriate wells. After 30 minutes of incubation at room temperature, the fluid was aspirated from the wells and the wells were washed 3 times with wash buffer. In a second step, 100 l of conjugate (anti-human IgG heavy chain specific, coupled with horseradish peroxidase) was added to each well. After incubation for 30 minutes at room temperature, the wells were washed 3 times with wash buffer. Thereafter, 100 l of enzyme substrate (3,3,5,5 -tetramethylbenzidine in citrate buffer containing hydrogen peroxide) was dispensed into the wells. After incubation in the dark for 10 minutes at room temperature, 100 l of stop solution (0.3M H 2 SO 4 ) was added to all wells. OD was read at 450 nm. According to the manufacturer s instructions, a result of 25 units/ml was considered positive. Detection of anti-ena and antihistone antibodies by line immunoassay. Sera were analyzed for anti-ena and antihistone antibodies by line immunoassay (LIA) (INNO-LIA ANA update K1090; Innogenetics, Zwijnaarde, Belgium). This multiparameter assay utilizes the following antigens: SmB, SmD, RNP 70, RNP-A, RNP-C, SSA/Ro 52, SSA/Ro 60, SSB/La, CENP-B, Scl-70, Jo-1, ribosomal P, and histones. The test was performed according to the manufacturer s instructions. Briefly, nylon strips were incubated with serum at a 1:200 dilution for 1 hour at room temperature. After washing 3 times with wash buffer, 2 ml of conjugate (anti-human IgG heavy and light chain specific, labeled with alkaline phosphatase) was added to all troughs and was allowed to bind to the antigen antibody complex if one was present. The strips were incubated for 30 minutes at room temperature. Thereafter, they were washed twice with wash buffer and once with substrate buffer before addition of 2 ml 5-bromo-4-chloro-3-indolyl phosphatase/nitroblue tetrazolium to each trough. The enzyme substrate and chromogen produced a dark brown color in proportion to the amount of specific autoantibody in the test sample. The strips were incubated for 30 minutes at room temperature. After aspiration of the liquid, 2 ml of stop solution (0.1M H 2 SO 4 ) was added to each trough to stop the color development. After minutes of incubation at room temperature, the fluid was aspirated and the strips were removed from the test troughs. The results were interpreted when the strips had dried completely. Monitoring for lupus-like symptoms. History-taking at every visit included questioning for any adverse event and, more specifically, active screening for fever or other symptoms suggestive of infection or rash. At the time of each infusion, erythrocyte sedimentation rate, C-reactive protein level, peripheral blood count, liver and kidney function, and levels of autoantibodies (ANA, anti-dsdna, anti-ena, antihistone) were tested. Urine was analyzed for proteinuria at the beginning and the end of the observation period. In order to evaluate lupus-like symptoms, we reviewed the medical charts of the RA and SpA patients who were positive for ANAs and anti-dsdna antibodies following infliximab treatment. The following components of the ACR classification criteria for systemic lupus erythematosus (SLE) could then be positively confirmed or ruled out (28,29): malar rash, discoid rash, photosensitivity, renal disorder, and hematologic disorder. The other SLE criteria (oral ulcers, serositis, and neurologic disorder) were assumed to be absent if symptoms were not reported by the patient. Statistical analysis. Statistical analysis was performed using SPSS software (SPSS, Chicago, IL). For dichotomous data, we used McNemar s test, which is suitable for paired analysis. When statistical analysis could not be performed because of empty rows in the crosstab, the value 1 was added to one cell. For comparison of proportions, we used a binomial test. P values less than or equal to 0.05 were considered significant. RESULTS Effect of infliximab treatment on ANAs in RA and SpA patients. At baseline, 32 of 62 RA patients (51.6%) and 6 of 35 SpA patients (17.1%) were positive

4 1018 DE RYCKE ET AL Table 1. Autoantibody profile in RA and SpA patients after infliximab treatment* RA (n 62) SpA (n 35) Antibody, detection method Week 0 Week 30 Week 0 Week 34 ANA, IIF on HEp-2 cells 32 (51.6) 51 (82.3) 6 (17.1) 31 (88.6) Anti-dsDNA IIF on Crithidia luciliae 0 (0) 27 (43.5) 0 (0) 20 (57.1) ELISA 2 (3.2) 10 (16.1) 6 (17.1) 6 (17.1) Both IIF on Crithidia luciliae and ELISA 0 (0) 7 (11.3) 0 (0) 6 (17.1) Antinucleosome, ELISA 1 (1.6) 5 (8.1) 3 (8.6) 4 (11.4) Antihistone, LIA 3 (4.8) 6 (9.7) 2 (5.7) 5 (14.3) Anti-SmD, LIA 1 (1.6) 1 (1.6) 0 (0) 0 (0) Anti-RNP, LIA 0 (0) 0 (0) 0 (0) 0 (0) Anti-SSA, LIA 0 (0) 0 (0) 0 (0) 0 (0) Anti-SSB, LIA 1 (1.6) 2 (3.2) 1 (2.9) 1 (2.9) Anticentromere, IIF/anti-CENP, LIA 1 (1.6) 1 (1.6) 0 (0) 0 (0) * Values are the number (%). RA rheumatoid arthritis; SpA spondylarthropathy; ANA antinuclear antibody; IIF indirect immunofluorescence; anti-dsdna anti double-stranded DNA; ELISA enzyme-linked immunosorbent assay; LIA line immunoassay. P versus baseline. P 0.01 versus baseline. P 0.05 versus baseline. for ANAs, most frequently with a homogeneous pattern (78.1% and 66.7%, respectively). After infliximab treatment, 51 of 62 RA patients (82.3%) had a positive result for ANAs at week 30, and 31 of 35 SpA patients (88.6%) tested positive for ANA at week 34 (both P versus baseline) (Table 1). The fluorescence pattern after infliximab treatment was most frequently homogeneous (92.2% and 93.5% in RA patients and SpA patients, respectively). Induction of ANAs was observed in both diseases, but was more pronounced in SpA than in RA: newly positive results for ANA were found in 20 RA patients (32.3%) and 25 SpA patients (71.4%) (P 0.001, RA versus SpA). Moreover, an increase in ANA intensity of 2 or more points (on a 0 5 scale) following infliximab therapy was observed in 28 RA patients (45.2%) compared with 26 SpA patients (74.3%) (P 0.001, RA versus SpA). Effect of infliximab treatment on anti-dsdna antibodies in RA and SpA patients. Initial screening by IIF on C luciliae and by ELISA revealed that at baseline, none of the 62 RA patients were positive by both assays for anti-dsdna antibodies. At week 30, 7 RA patients (11.3%) had developed anti-dsdna antibodies demonstrated in both assays (P versus baseline) (Table 1). Similarly, initial screening with IIF on C luciliae and ELISA showed no patient in the SpA population to have positive results on both assays for anti-dsdna antibodies at baseline. At week 34, 6 SpA patients (17.1%) were positive for anti-dsdna antibodies (P versus baseline) (Table 1). The induced anti-dsdna antibodies were further isotyped using,, and chain specific conjugates (Table 2). None of the 7 RA patients had anti-dsdna antibodies of the IgG class after 30 weeks of infliximab treatment, but all 7 were positive for anti-dsdna antibodies of the IgM and IgA class. At week 34, none of the 6 SpA patients had anti-dsdna antibodies of the IgG class, but 3 had anti-dsdna antibodies of both the IgM Table 2. Isotyping of anti-dsdna antibodies in RA and SpA patients after infliximab treatment* Anti-dsDNA antibodies at week 30 (RA patients) or week 34 (SpA patients) Patient IgG IgM IgA RA Total positive 0/7 7/7 7/7 SpA Total positive 0/6 5/6 3/6 * See Table 1 for definitions.

5 ANAs IN RA AND SpA PATIENTS TREATED WITH INFLIXIMAB 1019 Table 3. Detection and isotyping of anti-dsdna antibodies in RA patients at various time points* Anti-dsDNA antibody isotype IgG IgM IgA Patient Week 0 Week 30 Week 0 Week 2 Week 6 Week 14 Week 22 Week 30 Week 0 Week 2 Week 6 Week 14 Week 22 Week Total 0/7 0/7 0/7 0/7 5/7 7/7 7/7 7/7 1/7 1/7 1/7 1/7 1/7 7/7 * See Table 1 for definitions. and IgA class, and 2 had anti-dsdna antibodies of the IgM class alone. To study the timing of the induction of antidsdna antibodies in relation to infliximab treatment, we analyzed, at various time points during infliximab treatment, serum samples from the 7 RA and 6 SpA patients who had anti-dsdna antibodies at week 30 or 34 (Tables 3 and 4). None of the 7 RA patients had anti-dsdna antibodies of the IgM class at baseline. One RA patient was positive for anti-dsdna antibodies of the IgA class at baseline (by IIF on C luciliae with IgA-specific conjugate), and that patient remained positive up to week 30. Anti-dsDNA antibodies of the IgM class appeared in the majority of RA patients (5 of 7) at week 6, whereas anti-dsdna antibodies of the IgA class did not appear until week 30 in the 6 patients who were negative for these antibodies at baseline (Table 3). One SpA patient was positive for anti-dsdna antibodies of the IgM class at baseline, and, in another, anti-dsdna antibodies of the IgA class were detected at baseline (by IIF on C luciliae with IgA-specific conjugate). Both patients remained positive up to week 34. Induction of anti-dsdna antibodies occurred over a wider span of time in SpA than in RA. However, similar to the findings in RA, anti-dsdna antibodies of the IgM class appeared before anti-dsdna antibodies of the IgA class (Table 4). Effect of infliximab treatment on other antinuclear reactivities in RA and SpA patients. Antinucleosome antibodies detected by ELISA. One of the 62 RA patients (1.6%) had antinucleosome antibodies at baseline. At week 30, 5 RA patients (8.1%) tested positive for these antibodies (Table 1); the 1 RA patient who had a positive result at baseline remained positive, and 4 other RA patients became positive (P versus baseline). Two of the 7 RA patients with anti-dsdna antibodies at week 30 were also positive for antinucleosome antibodies at week 30. Among SpA patients, 3 of 35 (8.6%) had a positive result for antinucleosome antibodies at baseline. After 34 weeks of treatment with infliximab, 4 patients (11.4%) were positive (Table 1), including 2 of the 3 who were positive at baseline; 1 SpA patient with a positive result at baseline became negative, and 2 patients exhibited new development of antinucleosome antibodies (P versus baseline). Four of the 6 SpA patients with anti-dsdna antibodies at Table 4. Detection and isotyping of anti-dsdna antibodies in SpA patients at various time points* Anti-dsDNA antibody isotype IgG IgM IgA Patient Week 0 Week 30 Week 0 Week 2 Week 6 Week 12 Week 20 Week 34 Week 0 Week 2 Week 6 Week 12 Week 20 Week Total 0/6 0/6 1/6 2/6 4/6 5/6 6/6 5/6 1/6 1/6 1/6 1/6 2/6 3/6 * See Table 1 for definitions.

6 1020 DE RYCKE ET AL Table 5. Components of the ACR SLE criteria developing after infliximab treatment in the RA and SpA patients who had ANAs and anti-dsdna antibodies after treatment* Criterion RA (n 7) No. of patients SpA (n 6) Malar rash 0 0 Discoid rash 0 0 Photosensitivity 0 0 Oral ulcers 0 0 Serositis 0 0 Renal disorder 0 0 Neurologic disorder 0 0 Hematologic disorder 2 0 * ACR American College of Rheumatology; SLE systemic lupus erythematosus (see Table 1 for other definitions). Lymphopenia (defined as lymphocyte count 1,500/mm 3 ) in patient 1 (lymphocyte count [/mm 3 ] 1,850 at baseline, 1,100 at week 2, 3,060 at week 6, 3,180 at week 14, 850 at week 22, 1,290 at week 30); leukopenia (defined as white blood cell count 4,000/mm 3 ) in patient 4 (white blood cell count [/mm 3 ] 4,110 at baseline, 4,290 at week 2, 4,050 at week 6, 5,210 at week 14, 3,950 at week 22, 3,780 at week 30). week 34 were also positive for antinucleosome antibodies at week 34. Antihistone antibodies and anti-ena antibodies detected by LIA. At baseline, 4 of 62 RA patients (6.5%) had at least 1 fine reactivity on LIA (2 with reactivity to histones, 1 with reactivity to CENP-B and histones, 1 with reactivity to SSB and SmD). At week 30, 8 RA patients (12.9%) had at least 1 fine reactivity on LIA (P versus baseline). The 4 RA patients with a reactivity at baseline remained positive. Four other RA patients developed new reactivities after infliximab treatment (3 patients with reactivity to histones, 1 patient with reactivity to SSB) (Table 1). Three of 35 SpA patients (8.6%) were positive for at least 1 reactivity on LIA at baseline (2 patients with reactivity to histones and 1 with reactivity to SSB). At week 34, 6 of 35 SpA patients (17.1%) had at least 1 fine reactivity on LIA (P versus baseline). The 3 SpA patients with a reactivity at baseline remained positive, and 3 other SpA patients developed new reactivities to histones after treatment (Table 1). In both the RA group and the SpA group, no newly developed reactivities to SmD, RNP, SSA, or CENP-B could be detected. Detection of lupus-like characteristics in the RA and SpA patients with anti-dsdna antibodies after infliximab treatment. Autoantibodies to dsdna are highly specific for the diagnosis of SLE (30 33) and constitute one of the revised ACR classification criteria for this disease (28,29). We identified 7 RA and 6 SpA patients who tested positive for ANA and anti-dsdna antibodies following infliximab treatment. In 1 RA patient (patient 2), anti-smd antibodies were detected at baseline and that patient remained positive during infliximab treatment. In order to determine if any of these 7 RA and 6 SpA patients developed other, nonserologic lupus-like symptoms during infliximab treatment, we reviewed the medical charts for the ACR SLE classification criteria, as described in Patients and Methods. Since arthritis involving 2 or more peripheral joints was present in all 7 RA and 6 SpA patients as part of the underlying disease, this criterion could not be evaluated. Findings with regard to the remaining criteria indicating newly induced SLE are summarized in Table 5. The 7 RA and 6 SpA patients with anti-dsdna antibodies exhibited no clinical symptoms suggestive of SLE during the observational period, nor did proteinuria or cellular casts appear. Among the RA patients, 1 developed a mild leukopenia during infliximab treatment and another had an episode of lymphopenia. In SpA patients, no hematologic abnormalities were found. DISCUSSION Treatment with biologic agents directed against TNF, such as infliximab and etanercept (Enbrel; Wyeth-Ayerst, Philadelphia, PA), has significant clinical benefits in inflammatory diseases. Infliximab is registered by the Food and Drug Administration (FDA) and by the European Medicines Evaluation Agency (EMEA) as a therapy for treatment-resistant RA (6 11), treatment-resistant moderate-to-severe CD, and CD with fistulas (17 19). More recently, the efficacy of infliximab therapy has been proven in diseases that are within the SpA category (12 16). Etanercept is approved by the FDA and the EMEA for use in treatmentresistant RA, severe active, and progressive RA (34 38), and treatment-resistant polyarticular juvenile chronic arthritis (39,40), and by the FDA for treatment-resistant psoriatic arthritis (41). A beneficial effect of etanercept treatment in ankylosing spondylitis has also been demonstrated (42). The induction of ANAs (in 63.8% of RA patients and 49.1% of CD patients) and anti-dsdna antibodies (in 13% of RA patients and 21.5% of CD patients) after infliximab treatment has been reported (23). The development of ANAs and anti-dsdna antibodies after etanercept therapy in RA patients has also been described (in 11% and 15% of patients, respectively) (43). However, despite the development of ANAs and anti-dsdna antibodies in a fairly high proportion of patients during anti-tnf therapy, the incidence of possible lupus-like syndromes is low.

7 ANAs IN RA AND SpA PATIENTS TREATED WITH INFLIXIMAB 1021 Some case reports of lupus-like symptoms, with or without autoantibodies, occurring in patients receiving infliximab or etanercept treatment have been published (18,23,43 49), but it is difficult to determine whether these lupus-like symptoms are related to the anti-tnf treatment, to the underlying disease, to other drugs being taken concurrently, or whether they may have occurred coincidentally during anti-tnf treatment. The identification of drug-induced SLE among patients with RA is especially difficult, owing to the overlaps between the two diseases (25,28). Charles et al described the induction of antidsdna antibodies in 7% of RA patients treated with infliximab (with or without MTX therapy) and noted that the isotype of these antibodies differed from IgG (44). The current report extends the phenomenon of infliximab-induced ANAs to a new disease background, i.e., SpA. We confirm the high prevalence of ANAs and anti-dsdna antibodies in the latter disease following infliximab treatment. Moreover, the increase in ANA titers and the induction of anti-dsdna antibodies are more pronounced in SpA than in RA. However, ANAs might be more expected in untreated RA compared with SpA (50). Absence of associated MTX therapy in SpA may contribute to the observed difference. Of interest in this context is the observation, by Boehm et al, that MTX therapy could lead to a decrease in circulating autoantibodies in patients with cutaneous lupus (51). In our study, 11.3% of the RA patients and 17.1% of the SpA patients had anti-dsdna antibodies at the end of the observational period. Sera that converted to anti-dsdna positivity were further analyzed at different time points and isotyped. Isotyping revealed that none of the anti-dsdna antibodies had the IgG isotype (in RA, 7 of 7 IgM and 7 of 7 IgA; in SpA, 5 of 6 IgM and 3 of 6 IgA). In both diseases, IgM antidsdna antibodies appeared mostly in the first 6 weeks, prior to the appearance of anti-dsdna antibodies of the IgA isotype. The diagnostic and prognostic value of these anti-dsdna antibodies remains controversial since lupus-associated anti-dsdna antibodies are classically of the IgG isotype (30 33), while IgM or IgA anti-dsdna antibodies may occur in other diseases as well (mixed connective tissue disease, primary Sjögren s syndrome, scleroderma, RA, ankylosing spondylitis, chronic active hepatitis, primary biliary cirrhosis) (30,33,52). The non-igg isotype of the anti-dsdna antibodies detected in the present study, and the fact that we could not identify clinical or biologic features suggestive of lupus (other than anti-dsdna induction), suggest that clinically significant lupus induction did not occur. However, longer-term followup of these patients will be needed to counter that concern completely. Apart from the study of anti-dsdna antibodies, other ANA reactivities have not previously been systematically studied in relation to infliximab therapy. In this study, we additionally tested for antibodies to nucleosomes, histones, and ENA. Antinucleosome antibodies of the IgG class are considered to be a more sensitive marker for SLE than anti-dsdna antibodies, occurring at an earlier stage than anti-dsdna and antihistone antibodies (53). Although there was an increase in the number of patients with antinucleosome antibodies following infliximab treatment compared with baseline, this increase was not statistically significant. Antihistone antibodies are particularly common in SLE and druginduced lupus (with a sensitivity of 50 70% and 95%, respectively [32]), but may also occur in other diseases (RA, juvenile chronic arthritis, autoimmune chronic hepatitis, chronic infection) or even in healthy controls (32,54). In both the RA and the SpA groups, some patients exhibited new development of antihistone antibodies. However, this increase was not statistically significant in either disease group. Anti-ENA antibodies detected by LIA were rarely observed in RA or SpA. Only 1 RA patient developed a new anti-ena reactivity (anti-ssb antibodies). In conclusion, we confirm the induction of ANAs, and especially non-igg anti-dsdna antibodies, after infliximab treatment in patients with RA, and we present the first published report of the same phenomenon in SpA patients receiving this new treatment. The present data document that this particular serologic side effect is unrelated to the genetic background or the underlying disease process. The absence of IgG anti-dsdna antibodies, as well as the absence of other lupus-specific ANAs or clinical features in patients who developed anti-dsdna antibodies, are rather reassuring in terms of the safety of the treatment. However, longer-term observations of anti-dsdna positive patients remain mandatory. The mechanism of anti-dsdna antibody induction with anti-tnf therapy is still under study. ACKNOWLEDGMENT The authors thank Annette Heirwegh for excellent technical assistance. REFERENCES 1. Gabriel SE, Crowson CS, O Fallon WM. The epidemiology of rheumatoid arthritis in Rochester, Minnesota, Arthritis Rheum 1999;42:

8 1022 DE RYCKE ET AL 2. Saraux A, Guedes C, Allain J, Devauchelle V, Valls I, Lamour A, et al, Société de Rhumatologie de l Ouest. Prevalence of rheumatoid arthritis and spondyloarthropathy in Brittany, France. J Rheumatol 1999;26: Callahan LF, Pincus T, Huston JW III, Brooks RH, Nance EP Jr, Kaye JJ. Measures of activity and damage in rheumatoid arthritis: depiction of changes and prediction of mortality over five years. Arthritis Care Res 1997;10: Abu-Shakra M, Toker R, Flusser D, Flusser G, Friger M, Sukenik S, et al. Clinical and radiographic outcomes of rheumatoid arthritis patients not treated with disease-modifying drugs. Arthritis Rheum 1998;41: McQueen FM, Stewart N, Crabbe J, Robinson E, Yeoman S, Tan PL, et al. Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals progression of erosions despite clinical improvement. Ann Rheum Dis 1999;58: Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor. Arthritis Rheum 1993;36: Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor (ca2) versus placebo in rheumatoid arthritis. Lancet 1994;344: Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, MacFarlane JD, et al. Therapeutic efficacy of multiple infusions of anti tumor necrosis factor monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41: Maini RN, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al, ATTRACT Study Group. Infliximab (chimeric antitumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999;345: Lipsky PE, van der Heijde DMFM, St. Clair EW, Furst DE, Breedveld FC, Kalden JR, et al, for the Anti Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343: Kavanaugh A, St Clair EW, McCune WJ, Braakman T, Lipsky P. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J Rheumatol 2000;27: Van den Bosch F, Kruithof E, de Vos M, de Keyser F, Mielants H. Crohn s disease associated with spondyloarthropathy: effect of TNF- blockade with infliximab on articular symptoms. Lancet 2000;35: Van den Bosch F, Kruithof E, Baeten D, de Keyser F, Mielants H, Veys EM. Effects of a loading dose regimen of 3 infusions of chimeric monoclonal antibody to tumour necrosis factor (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis 2000;59: Brandt J, Haibel H, Cornely D, Golder W, Gonzales J, Reddig J, et al. Successful treatment of active ankylosing spondylitis with the anti tumor necrosis factor monoclonal antibody infliximab. Arthritis Rheum 2000;43: Van den Bosch F, Kruithof E, Baeten D, Herssens A, de Keyser F, Mielants H, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum 2002;46: Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002;359: Targan SR, Hanauer SB, van Deventer SJH, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody ca2 to tumor necrosis factor for Crohn s disease. N Engl J Med 1997;337: Rutgeerts P, D Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, et al. Efficacy and safety of retreatment with antitumor necrosis factor antibody (infliximab) to maintain remission in Crohn s disease. Gastroenterology 1999;117: Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn s disease. N Engl J Med 1999;340: Markham A, Lamb HM. Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs 2000;59: Keane J, Gershon S, Wise RP, Miraibile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345: Van den Bosch F, de Keyser F, Joos R, Kruithof E, Noe A, Baeten D, et al. Reactivation of tuberculosis in 2 patients with spondyloarthropathy treated with infliximab [abstract]. Arthritis Rheum 2001;44 Suppl 9:S Centocor, Inc. Remicade (infliximab). Data on file. 24. Durez P, Devogelaer JP, van den Bosch F, Kruithof E, Perets A, Verbruggen L, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis: clinical results in a Belgian observational cohort [abstract]. Arthritis Rheum 2001;44 Suppl 9:S Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31: Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991;34: Humbel RL. Detection of antinuclear antibodies by immunofluorescence. In: Van Venrooij WJ, Maini RN, editors. Manual of biological markers of disease. Dordrecht, The Netherlands: Kluwer Academic Publishers; A2: p Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25: Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40: Werle E, Blazek M, Fiehn W. The clinical significance of measuring different anti-dsdna antibodies by using the Farr assay, an enzyme immunoassay and a Crithidia luciliae immunofluorescence test. Lupus 1992;1: Hylkema MN, Huygen H, Kramers C, van der Wal TJ, de Jong J, van Bruggen MC, et al. Clinical evaluation of a modified ELISA, using photobiotinylated DNA, for the detection of anti-dna antibodies. J Immunol Methods 1994;170: Von Mühlen CA, Tan EM. Autoantibodies in diagnosis of systemic rheumatic diseases. Semin Arthritis Rheum 1995;24: Bootsma H, Spronk PE, Hummel EJ, de Boer G, ter Borg EJ, Limburg PC, et al. Anti-double stranded DNA antibodies in systemic lupus erythematosus: detection and clinical relevance of IgM-class antibodies. Scand J Rheumatol 1996;25: Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-fc fusion protein. N Engl J Med 1997;337: Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340:253 9.

9 ANAs IN RA AND SpA PATIENTS TREATED WITH INFLIXIMAB Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 1999;130: Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: Moreland LW, Cohen SB, Baumgartner SW, Tindall EA, Bulpitt K, Martin R, et al. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol 2001;28: Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al, Pediatric Rheumatology Collaborative Study Group. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000;342: Kietz DA, Pepmueller PH, Moore TL. Therapeutic use of etanercept in polyarticular course juvenile idiopathic arthritis over a two year period. Ann Rheum Dis 2002;61: Mease PJ, Goffe BS, Metz J, vander Stoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356: Gorman JD, Sack KE, Davis JC. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor. N Engl J Med 2002;346: Immunex Corp. Enbrel (etanercept). Data on file. 44. Charles PJ, Smeenk RJT, de Jong J, Feldmann M, Maini RN. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor : findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000;43: Shakoor N, Michilska M, Harris CA, Block JA. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002;359: Brion PH, Mittal-Henkel A, Kalunian KC. Autoimmune skin rashes associated with etanercept for rheumatoid arthritis [letter]. Ann Intern Med 1999;131: De Bandt MJ, Descamps V, Meyer O. Two cases of etanerceptinduced systemic lupus erythematosus in patients with rheumatoid arthritis [abstract]. Ann Rheum Dis 2001;60: Bleumink GS, ter Borg EJ, Ramselaar CG, Stricker BHCh. Etanercept-induced subacute cutaneous lupus erythematosus. Rheumatology 2001;40: Misery L, Perrot JL, Gentil-Perret A, Pallot-Prades B, Cambazard F, Alexandre C. Dermatological complications of etanercept therapy for rheumatoid arthritis. Br J Dermatol 2002;146: Sulcebe G, Morcka K. Diagnostic and prognostic significance of different antinuclear antibodies in more than 1000 consecutive Albanian patients with rheumatic diseases. Clin Exp Rheumatol 1992;10: Boehm IB, Boehm GA, Bauer R. Management of cutaneous lupus erythematosus with low-dose methotrexate: indication for modulation of inflammatory mechanisms. Rheumatol Int 1998;18: Miltenburg AMM, Roos A, Slegtenhorst L, Daha MR, Breedveld FC. IgA anti-dsdna antibodies in SLE: occurrence, incidence and association with clinical and laboratory variables of disease activity. J Rheumatol 1993;20: Amoura Z, Koutouzov S, Piette JC. The role of nucleosomes in lupus. Curr Opin Rheumatol 2000;12: Bernstein R. Autoantibodies to histones, Sm and ubiquitins. In: Van Venrooij WJ, Maini RN, editors. Manual of biological markers of disease. Dordrecht, The Netherlands: Kluwer Academic Publishers; C2: p. 1 7.